OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S
(Thomson Reuters ONE) -
Leiden, the Netherlands, 2 February 2012 - OctoPlus N.V. ("OctoPlus" or the
"Company") (Euronext: OCTO), announces today that a formulation development and
manufacturing contract has been signed with Ferring Pharmaceuticals A/S, a
leading innovative pharmaceutical company. The undisclosed contract value will
make a material contribution to OctoPlus' 2012 revenues. Further details on the
compound and activities are not disclosed.
At OctoPlus we provide formulation development and clinical material
manufacturing services to biotech and pharmaceutical companies worldwide. In
addition to our expertise in formulation and manufacturing, we offer our clients
drug delivery technologies for the development of controlled release versions of
existing or new drugs.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or
send an e-mail to Investor Relations atIR(at)octoplus.nl.
About OctoPlus
OctoPlus is a specialty pharmaceutical company focused on the development and
manufacture of improved injectable pharmaceuticals based on our proprietary drug
delivery technologies that exhibit fewer side effects, improved patient
convenience and a better efficacy/safety balance than existing therapies.
OctoPlus also focuses on the development of long-acting, controlled release
versions of known protein therapeutics, peptides and small molecules, including
specialty generics.
The clinically most advanced product incorporating our technology is
Locteron(®), a controlled release formulation of interferon alpha for the
treatment of chronic hepatitis C. OctoPlus licensed Locteron exclusively to
Biolex in October 2008. Locteron is being manufactured for Biolex by OctoPlus
and has recently completed Phase IIb clinical studies with superior clinical
data versus current treatment.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF format:
http://hugin.info/137076/R/1582008/494231.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1582008]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.02.2012 - 01:30 Uhr
Sprache: Deutsch
News-ID 1078725
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Leiden
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 55 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus enters into drug development and manufacturing contract with Ferring Pharmaceuticals A/S
"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
